Navigation Links
Blood transfusion study: Less is more
Date:8/5/2009

A new study suggests that blood transfusions for hospitalized cardiac patients should be a last resort because they double the risk of infection and increase by four times the risk of death.

The analysis of nearly 25,000 Medicare patients in Michigan also showed that transfusion practices after heart surgery varied substantially among hospitals, a red flag that plays into the health care reform debate.

A wide variation in care is a hot-button issue, as lawmakers and health reform experts discuss the best ways to address the variations. Some experts believe the country needs a system of medical guidelines, supported by scientific evidence, to aid doctors in decision-making. In fact, the Institute of Medicine has called for a national initiative of comparing the benefits and harms of certain methods to improve the delivery of care -- an effort referred to by health-care insiders as "comparative effectiveness" research.

Blood transfusion is an area that could be well served with stronger, research-based guidelines, since the current clinical practice is all over the map, said study co-author Neil Blumberg, M.D., professor of Pathology and Laboratory Medicine and director of Transfusion Medicine at the University of Rochester Medical Center.

"Doctors are simply doing what they were trained to do, but it turns out that their actions are more harmful than helpful in many cases," Blumberg said. "This is an instance in which clinical practice got way ahead of research. And changing the liberal use of transfusions is going to be difficult despite the evidence showing it is usually not essential."

The study was published July 31, 2009 in the journal, BMC Medicine. It was designed to assess patient outcomes as well as hospital variation in blood use.

Blumberg and lead author Mary Rogers, Ph.D., of the University of Michigan Health System, analyzed patient records in 40 hospitals, from admission to 30 days af
'/>"/>

Contact: Karin Christensen
karin_christensen@urmc.rochester.edu
585-275-1311
University of Rochester Medical Center
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Gut Hormone Could be Key to Blood Sugar
2. GenVaults GenSolve(TM) Reagents Enable State-of-the-Art Genomic Analysis of Dried Blood Spots
3. Silenced genes as a warning sign of blood cancer
4. Young Kids Screen Time May Raise Blood Pressure
5. Blood Type May Boost Pancreatic Cancer Risk
6. Patients Issue Summer Call to Action: We Need You to Donate Blood -- NOW
7. Blood Transfusions Not Linked to Long-Term Problems
8. UF scientists program blood stem cells to become vision cells
9. Makers of the High-Tech Thermal Angel Blood Warmer Say Lawmakers Should Look for Private Sector Solutions During Health Care Debate
10. Food additive may one day help control blood lipids and reduce disease risk
11. Eagles to Host 2nd Annual American Red Cross Training Camp Blood Drive
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Dynatronics Receives 180-Day NASDAQ Extension 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 3Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 2Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 3U S Food and Drug Administration Clears Vermillions OVA1 28TM 29 Test to Determine Likelihood of Ovarian Cancer in Women with Pelvic Mass 56963 1U S Food and Drug Administration Clears Vermillions OVA1 28TM 29 Test to Determine Likelihood of Ovarian Cancer in Women with Pelvic Mass 56963 2U S Food and Drug Administration Clears Vermillions OVA1 28TM 29 Test to Determine Likelihood of Ovarian Cancer in Women with Pelvic Mass 56963 3U S Food and Drug Administration Clears Vermillions OVA1 28TM 29 Test to Determine Likelihood of Ovarian Cancer in Women with Pelvic Mass 56963 4U S Food and Drug Administration Clears Vermillions OVA1 28TM 29 Test to Determine Likelihood of Ovarian Cancer in Women with Pelvic Mass 56963 5West to Present at Two Upcoming Investor Conferences 56960 1West to Present at Two Upcoming Investor Conferences 56960 2Early results from clinical trials of 2009 H1N1 influenza vaccines in healthy adults 56959 1Early results from clinical trials of 2009 H1N1 influenza vaccines in healthy adults 56959 2